Company ProfilePremium

CXI Healthcare Technology Group Limited (formerly CKH Food & Health Limited)

Company Profile Analysis

Ticker: 900120.KQ씨엑스아이헬스케어테크놀리지그룹리미티드

ESOMAR 23 Corporate BadgeISO Certifications Badge
CXI Healthcare Technology Group Limited - Company showcase

Year Founded & Workforce

2009

378 Employees

CXI Healthcare Technology Group Limited logo

CXI Healthcare Technology Group Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

CXI Healthcare Technology Group Limited Overview

CXI Healthcare Technology Group is a Cayman-incorporated holding company listed on KOSDAQ. Its operating businesses are in Fujian Province, China. It manufactures health supplements based on traditional Chinese medicine (TCM), sold as capsules, tablets, granules, drinks and teas, and distributes raw materials such as cordyceps, tea leaves and herbal inputs [S1][S37]. Since 2019 it has added a small cosmetics-distribution business, which brings Korean and Japanese skincare brands into China [S8][S15]. Earlier in its listed life the company reported revenue in the hundreds of billions of KRW. In FY2025 revenue fell to KRW 57.6 bn [S2], and recent quarters show gross losses [S27]. The balance sheet is large and almost debt-free (equity KRW 491.6 bn at June 2025) [S2], yet the market capitalisation is a small fraction of book value. In 2026 the company recapitalised under its CEO to stay listed under tighter KOSDAQ rules. In October 2026 it agreed to buy 55% of a Chinese enterprise-AI data company, which redirects the group toward AI services [S3][S5].


What the company does

Self-description. In its filings and profiles, the group says it makes and sells health foods in China through subsidiaries. The products are TCM-based supplements in capsule, tablet, drink and tea formats [S1][S30]. A Korean-language profile derived from the company's disclosures adds three points [S37]:

  • the group runs a raw-material distribution business covering cordyceps and tea leaves;

  • the cosmetics unit sells TUNEMAKERS skincare through JD.com, Tmall Global and other major online platforms.

Morningstar's profile states that all products are marketed only in China [S30].

Independent characterisation. CXI is a small, mostly domestic Chinese consumer-health company. Its listed shell has been used repeatedly for capital-structure transactions, and it is now being repositioned. Three features stand out:

  1. Operating shrinkage. Revenue moved from the mid-2010s scale cited in Korean press to KRW 57.6 bn in FY2025 [S2]. It then fell to a run-rate below KRW 8 bn per quarter by the March 2026 quarter [S27].

  2. Asset-heavy, cash-and-plantation balance sheet. Total assets were KRW 575.2 bn at March 2026 [S26], against trailing revenue of KRW 51.4 bn [S25]. Depreciation and amortisation embedded in cost of sales was about KRW 24–26 bn per year [S25], which points to large plantation or land-use assets.

  3. Strategic pivot to AI. The October 2026 decision to buy 55% of AIDT Technologies Limited [S3] would make AI data services the largest revenue line on consolidation. AIDT's H1 2026 revenue (USD 36.97 m, about KRW 53.6 bn) is larger than CXI's trailing twelve-month revenue [S3][S25].

Business model and revenue model

Revenue typeDescriptionApproximate weight
Product sales: health supplementsOwn-manufactured TCM-based supplements (capsules, tablets, granules, drinks), sold to distributors and retailersNot publicly disclosed (FY2025)
Product sales: general foods / teaTraditional teas, including Pu'er from an acquired plantation—
Distribution: raw materialsTrading of cordyceps, herbal inputs and tea leaves, at lower margin—
Distribution: cosmeticsExclusive or general distribution of third-party brands (TUNEMAKERS, Answer Garden) and co-developed productsNot publicly disclosed; small
Prospective: AI services (AIDT)AI data collection and processing, data governance, model training and fine-tuning, industry AI applicationsNot yet consolidated as of the decision date

There is no subscription or licensing revenue. The model is product and trading revenue. In 2012 management gave segment gross-margin guides of about 70% for health foods, 20–30% for distribution and about 50% for tea [S22]. Current segment margins are not disclosed.

Value-chain position

The group is vertically integrated from cultivation to branded product. It acquired a large Chinese-herbal plantation in 2015 [S16] and a Pu'er tea plantation in 2020 [S10]. It runs a tea-cultivation complex and a research lab [S8], manufactures in Fujian [S18], and sells through distributors and retail. In cosmetics it acts as a brand distributor or incubator, not a manufacturer [S7][S15].

Customers and end-markets

Channels (health foods): Hypermarkets, supermarkets, pharmacies, health-food specialty stores and tea houses, mostly through wholesale or general distributors (총판) [S18].

Channels (cosmetics): JD.com, Taobao, Tmall Global and Xiaohongshu online. Offline, the business supplies franchise cosmetics retailers and agents. A Watsons China supply agreement was signed in October 2020 [S17].

End-markets: Chinese consumer health and wellness, Chinese tea, Chinese skincare and, prospectively, Chinese enterprise AI.

Strategy

Stated strategy (paraphrased from company statements)

In February 2026 the company described a programme to keep its listing, protect shareholder value and restore the share price. It rested on four pillars [S6]:

  1. profitability-focused management;

  2. stronger competitiveness of the core business;

  3. securing new growth engines;

  4. better financial soundness and management efficiency.

Management added that it would consider any other reasonable measure to meet listing requirements and leave "low-priced stock" status [S6].

In March 2026 the company presented the capital reduction as groundwork for future shareholder-return policies, including possible dividends, and not as a response to financial distress [S2].

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

DateInitiativeTypeDetailSource
Oct 2024Beautyskin placement and MOUPartnership / cosmeticsKRW 1.0 bn equity from Beautyskin; joint R&D on tea-leaf extracts; cross-distribution[S8]
Jul–Aug 202510:1 share consolidationCapital structureShares to 30,054,138[S11]
Oct 2025K-indie brand strategy; Answer Garden distributionNew business lineDedicated task force for brand incubation and sourcing; more brands targeted within the year[S7]
Feb 2026Listing-maintenance and value-up programmeGovernance / strategyFour pillars (above)[S6]
Mar 2026CEO premium placement with 3-year lock-upCapital / governanceKRW 730 per share, 67.7% premium[S4]
Mar–Jun 202680% par reduction and 5:1 consolidationCapital structurePre-empts the 1 Jul 2026 KOSDAQ rules (KRW 20 bn market-cap floor; delisting route for sub-KRW 1,000 stocks)[S2]
Jun 2026Second CEO placementCapitalCEO's March and June investments total about KRW 10.7 bn[S5]
Jul–Aug 2026KRW 48 bn third-party placementCapitalCEO KRW 19.2 bn for 3.2 m shares[S5][S12]
Jul 2026CEO on-market purchase planGovernance signal700,000 shares (4.2% of shares as then stated), 8 Oct – 6 Nov 2026, about KRW 760 m[S5]
Oct 2026AIDT Technologies 55% acquisitionTransformational M&AUSD 45.37 m; enterprise AI data and software[S3]

Medium-term targets / guidance

No quantitative revenue, margin or return targets were disclosed in the sources reviewed. The only forward-looking figures relate to AIDT and come from an external valuation firm: consolidated AIDT revenue of about USD 52.07 m in 2027 and about 40% compound annual growth through 2029 [S3].

ESG / sustainability commitments

None disclosed. The Answer Garden brand that CXI distributes promotes natural ingredients and recyclable packaging [S7], but that is a brand attribute, not a group commitment.

Products & Services

Health Supplements (own manufacture)

Product / lineDescription and claimed functionTarget customerLaunch / latest yearPricingSource
영생활력 ("Yongsheng Huoli") brand, incl. anti-aging/fatigue lineFlagship TCM-herbal supplement brand in capsule, tablet, granule and tea formats; positioned for fatigue improvement and anti-agingAdult Chinese consumersMain brand cited 2020–2025—[S10][S13][S37]
Cordyceps-based supplementsProducts using cultured cordyceps; the company claims small amounts of cordyceps achieve efficacy through its cultivation method. Cordyceps was the largest sales item as of 2022Adult/middle-aged consumersSince founding—[S21][S13]
금려강 Capsules (Jinlijiang)Menopausal-symptom relief; 12% of FY2009 salesWomen in menopausePre-IPO—[S20]
건력강 Tablets (Jianlijiang)Male sexual-function support; 12% of FY2009 salesAdult menPre-IPO—[S20]
삼청보 Tablets (Sanqingbao)Constipation relief; 9% of FY2009 salesGeneral adultPre-IPO—[S20]
건뇌영 Capsules (Jiannaoning)Fatigue recovery; 6% of FY2009 salesGeneral adultPre-IPO—[S20]
12-product new supplement pipelineImmunity, digestion, diabetes adjunct and memory improvement; awaited CFDA administrative approval in Oct 2016.Adults2016–2017 (expected)—[S16][S23]
Cistanche (종용) productsDomestic Chinese health products based on cistancheAdultsCited 2022—[S13]

General Foods / Tea

Product / lineDescriptionSource
Traditional teasPremium and traditional tea; the general-foods division recovered in FY2021[S10][S18]
Pu'er teaFrom the plantation acquired in 2020; described by the company as high-margin[S10][S13]

Raw Material Distribution

ProductDescriptionSource
Cordyceps (동충하초)Distribution of cordyceps raw material[S18][S37]
TCM herbal inputsFrom the herbal cultivation complex acquired in 2015; primary processing[S16]
Tea leavesDistribution from cultivation assets[S37]

Cosmetics (distribution and co-development)

Brand / productOwner / partnerScopeYearSource
Mask packs (own or co-developed)Korean partners (Humedix MOU)Watsons China online and offline; JD.com, Taobao, Tmall Global, Xiaohongshu. Jun–Sep 2020 sales of about RMB 1.03 m. Ampoule and sunscreen line extensions planned2,020[S9][S17]
TUNEMAKERSRAFRA (Japan; acquired by Unilever in Oct 2019)Distribution in China. The brand's prior-year China sales were cited at about RMB 200 m2,022[S15]
Answer GardenKovix (Korean manufacturer)Exclusive China distribution of 15 SKUs: ampoule, toner, foam cleanser, moisturising cream, mist and mask pack. A dedicated task force will incubate further K-indie brands2,025[S7]
Beautyskin co-developmentBeautyskin (Korea-listed)Joint R&D on tea-leaf-extract cosmetic ingredients using CXI's tea complex and lab; cross-distribution2,024[S8]

Prospective: AI Services (AIDT Technologies)

OfferingDescriptionSource
AI data collection and processingCore business[S3]
Data governanceExtended service line[S3]
AI model training and fine-tuningExtended service line[S3]
Industry-specific AI applicationsEnterprise AI software[S3]

Financial Narrative

Income statement

Sources and derivations:

  • FY2024 revenue, operating income and net income come from a DART-derived summary [S11].

  • FY2025 revenue and net income come from the company statement [S2].

  • FY2025 cost of revenue (KRW 40.32 bn) comes from Valueline [S25]. FY2025 gross profit is derived (57.63 − 40.32). FY2025 revenue in [S25] (57.63) matches [S2] (57.6).

  • Margins and growth are derived.

FY2026: (year to June 2026): the annual report was due by about end-September 2026, but its figures were not located. Nine-month data are in 6.2.

  • EBITDA, pre-tax income, EPS (basic/diluted) and DPS: not publicly disclosed in sources reviewed. Google Finance shows an EPS of KRW 1,662 [S27], but its share basis and period are unclear and inconsistent with the net income and share counts above, so it is not relied upon. No dividends were paid [S28].

Quarterly trend — FY2025 Q4 to FY2026 Q3

Sources: Google Finance quarterly data [S27]. Operating income for Q1–Q3 FY26 is derived as revenue minus total operating expenses. Net income for Q2 and Q3 FY26 is from TradingView [S28], which reports the last two quarters as −1.50 bn and −2.45 bn.

Cross-check. The four quarters sum to KRW 51.44 bn. This matches Valueline's trailing-twelve-month (TTM) revenue to March 2026 of KRW 51.44 bn [S25], so the quarterly series is internally consistent.

Nine-month comparison (derived). Revenue for 9M FY2026 was KRW 32.14 bn, against KRW 38.33 bn for 9M FY2025 (57.63 − 19.30). That is a decline of about 16%.

Trailing-twelve-month trend

Source: Valueline annualised series [S25]. Column mapping was verified against the FY2025 company figures [S2] and the Simply Wall St TTM to December 2025 (revenue KRW 54.2 bn, cost of revenue 38.6 bn, gross profit 15.5 bn, earnings 9.9 bn) [S1].

Key observation. Depreciation and amortisation inside cost of revenue rose from about 57% to about 70% of cost of revenue over the period. As a share of revenue it reached about 50% in TTM March 2026 (derived). Raw-material cost fell by roughly a third. The cost base is therefore dominated by fixed asset charges, most plausibly plantation, biological or land-use assets, rather than by variable inputs. This explains why falling sales turned into quarterly gross losses.

Balance sheet

Interim position at 31 March 2026 (Valueline):

  • total assets KRW 575.24 bn;

  • current assets KRW 55.17 bn;

  • cash KRW 47.08 bn;

  • derived non-current assets KRW 520.07 bn [S26].

Sources: Valueline balance sheet [S26]. Liabilities and equity for FY2024 come from [S11] and for FY2025 from [S2]. The FY2025 total assets of 494.2 match across [S2] and [S26]. Goodwill and intangibles, the short/long-term debt split and working-capital detail were not publicly disclosed in sources reviewed. Total liabilities of KRW 2.5 bn at June 2025 [S2] imply no material interest-bearing borrowings.

Red flag requiring scrutiny. Between June 2025 and March 2026:

  • cash fell by about KRW 153 bn (200.5 to 47.1);

  • non-current assets rose by about KRW 245 bn (275.2 to 520.1);

  • total assets rose by about KRW 81 bn (494.2 to 575.2).

Over the same period the group reported net losses in two of three quarters [S28]. Its only disclosed equity inflow before April 2026 was the March 2026 CEO placement (about 7.3 m pre-consolidation shares at KRW 730, roughly KRW 5.3 bn; derived from [S4][S11]). Liabilities had been about KRW 2.5 bn [S2]. Possible explanations include:

  • reclassification of cash into long-term deposits, loans or investments;

  • prepayments for acquisitions;

  • foreign-currency translation effects.

None of these could be verified. The movement should be reconciled against the FY2026 audited statements before any reliance is placed on book value. Note also that the company said in 2022 that IPO proceeds had been moved to the PRC operating entity as intra-group operating loans [S13].

Data conflicts and period attribution

  1. FY2024 vs FY2023 labelling. The Digital Today AI disclosure summary (August 2025) labels revenue of KRW 70.4 bn, operating profit of KRW 19.1 bn, net income of KRW 29.7 bn, assets of KRW 483.9 bn, liabilities of KRW 2.7 bn and equity of KRW 481.1 bn as "June 2023" [S11]. Valueline's June 2024 column shows total assets of KRW 483.86 bn, while its June 2023 column shows KRW 415.97 bn [S26]. In August 2025 the latest audited year was FY2024. Users should confirm against DART.

  2. Historic scale. Hankyung (April 2015) cites prior-year revenue of KRW 153.5 bn and operating profit of KRW 49.4 bn. The same article quotes a broker forecast of KRW 324.4 bn revenue and KRW 106.3 bn operating profit as +13.3% and +15.9% growth, which implies a base of about KRW 286 bn and 92 bn [S23]. A 2016 interview cites the prior year at KRW 297.6 bn revenue and KRW 70.5 bn operating profit [S16]. A 2014 broker note forecast FY2014 operating profit of KRW 102.9 bn [S24]. These figures cannot all be correct. Either the definitions or the periods differ (possibly half-year vs full-year, or currency-translation bases). They establish only that the business was several times larger in the mid-2010s than in FY2025.

  3. P/E and P/B on aggregator sites. StockHub shows P/E 0.73–0.80 and P/B 0.01 [S29]. These appear to use stale share counts.

Cash flow

Cash-flow statements were not publicly disclosed in sources reviewed. TradingView states that the company does not pay dividends [S28]. No company share buyback programme was identified. The CEO's personal on-market purchase plan is not a company buyback.

Ratios (derived)

Derivations:

  • FY2025 ROE uses average equity (481.1 + 491.6)/2. StockHub's 2.53% ROE [S29] is consistent.

  • ROA uses average assets.

  • Asset turnover is revenue divided by average total assets.

  • Not computable: ROIC, current ratio, interest coverage, net debt/EBITDA and the cash conversion cycle, because current liabilities, interest and working-capital detail were not disclosed. With total liabilities of only KRW 2.5 bn against current assets of KRW 219.0 bn at June 2025, the current ratio was at least 87x (derived lower bound). Interest coverage is effectively not meaningful because there is no disclosed debt.

  • 5-year revenue CAGR: not computable from verified data.

Commentary: trends, inflections, drivers

Revenue. Revenue has fallen from a mid-2010s base reported in the hundreds of billions of KRW [S16][S23] to KRW 70.4 bn in FY2024, KRW 57.6 bn in FY2025 and KRW 51.4 bn TTM to March 2026 [S11][S2][S25]. The break came in the December 2025 quarter, when revenue more than halved from 16.75 bn to 7.87 bn [S27]. The company has not given a public explanation for that drop in the sources reviewed. The Chinese supplement industry was weak at the same time. By-health, the category leader, reported falling pharmacy footfall and offline supplement sales [S32]. That industry weakness is relevant context, not a confirmed cause.

Margins. Reported profitability was high: a 27.1% operating margin and 42.2% net margin in FY2024, with net income above operating income, which implies large non-operating income such as interest on cash [S11]. FY2025 was weaker at a 22.1% net margin and roughly 30% gross margin [S2][S25]. With depreciation of about KRW 6 bn per quarter fixed in cost of sales, the falling revenue produced gross losses in the last two reported quarters [S27].

Balance sheet. For years the market valued the company at a small fraction of book value, which management itself cited as a long-running undervaluation [S2].

Inflection. If the AIDT acquisition closes, it would roughly double consolidated revenue. AIDT's H1 2026 revenue was USD 36.97 m, about KRW 53.6 bn [S3]. It would also replace the declining health-food P&L as the main earnings driver, with 45% of AIDT's earnings attributable to non-controlling interests.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityJurisdictionRoleOwnership

CXI Healthcare Technology Group Limited

Cayman Islands

Listed holding company

—

Fujian Jinshan Dadao Biotech Co., Ltd. (복건금산대도생물과기)

PRC (Fujian)

Principal operating subsidiary

100% (at IPO)

Fuzhou Jinda Bioengineering Technology Development Co. (복주금대생물공정과기개발)

PRC (Fujian)

Operating sub-subsidiary

100% indirect (at IPO)

Jinshan Resources Investment Co., Ltd. (금산자원투자)

Not stated

Group entity shown in 2019 IR structure

—

CKH Health Industry Co., Ltd. (씨케이에이치건강산업)

Republic of Korea

Cosmetics sourcing and distribution

100%

Jieya Star (JIEYA STAR)

Not stated (PRC operating sub)

Cosmetics/consumer distributor

—

AIDT Technologies Limited

Not stated

Enterprise AI data and software

—

“—” = not publicly disclosed.

Revenue by Segment

SegmentFY2024FY2025

Total revenue (KRW Bn)

70.457.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%)

MetricFY2024FY2025

Revenue (KRW Bn)

70.457.6

Cost of revenue (KRW Bn)

—40.3

Gross profit (KRW Bn)

—17.3

Operating income (KRW Bn)

19.1—

Net income (KRW Bn)

29.712.7

Gross margin (%)

—30.0

Operating margin (%)

27.1—

Net margin (%)

42.222.1

Revenue growth YoY (%)

—-18.2

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement

MetricQ4 FY25 (Apr–Jun 2025)Q1 FY26 (Jul–Sep 2025)Q2 FY26 (Oct–Dec 2025)Q3 FY26 (Jan–Mar 2026)

Revenue (KRW Bn)

19.3016.757.877.52

Cost of goods sold (KRW Bn)

9.3010.079.568.20

Gross profit (KRW Bn)

10.006.68-1.69-0.68

SG&A (KRW Bn)

2.091.792.281.80

Total operating expenses incl. COGS (KRW Bn)

11.7311.8011.5410.02

Operating income (KRW Bn)

7.574.95-3.67-2.50

Net income (KRW Bn)

——-2.45-1.50

Income Statement (Annual)

MetricTTM Mar-2025FY Jun-2025TTM Sep-2025TTM Dec-2025TTM Mar-2026

Revenue (KRW Bn)

64.3957.6355.7354.1551.44

Cost of revenue (KRW Bn)

39.6640.3239.1838.6137.13

of which raw materials (KRW Bn)

16.9916.1914.9713.6211.20

of which depreciation & amortisation (KRW Bn)

22.7324.0124.1024.9925.82

Net income (KRW Bn)

23.6112.7411.229.928.65

Balance Sheet

MetricFY2022FY2023FY2024FY2025

Total assets (KRW Bn)

427.86415.97483.86494.17

Current assets (KRW Bn)

99.85121.30187.11218.98

Cash & equivalents (KRW Bn)

65.7194.62159.91200.53

Total liabilities (KRW Bn)

——2.72.5

Total equity (KRW Bn)

——481.1491.6

Non-current assets (KRW Bn, derived)

328.01294.67296.75275.19

Financial Analysis

MetricFY2022FY2023FY2024FY2025FY2026

Dividends paid (KRW Bn)

00000

Margin Analysis (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025

ROE (%)

——6.22.6

ROA (%)

——6.62.6

Liabilities / equity (%)

——0.560.51

Cash / total assets (%)

15.422.733.040.6

Asset turnover (x)

——0.150.12

Revenue by Region

RegionFY2024FY2025

China (KRW Bn)

70.457.6

Capital Markets

ItemValueDate

Last verified close

KRW 4,595 (+29.99%)

14 Oct 2026

Market cap

about KRW 52.1 bn

14 Oct 2026

52-week range (as shown)

KRW 324 – 5,430

Oct 2026

Prior snapshots

KRW 1,053 (26 Jun 2026); KRW 1,091 (16 Jul 2026); KRW 1,168 (24 Jul 2026); KRW 851 (3 Aug 2026), all before the 27 Aug consolidation

2026

All-time high / low (pre-consolidation basis)

KRW 5,524 (30 Apr 2015) / KRW 49 (7 Apr 2025)

—

1-year performance

−38.61% (TradingView snapshot, mid-2025, pre-consolidation)

2025

3- and 5-year performance

Not reliably computable.

—

Shares in Issue by Date

DateShares in issueBasis

Mar 2010

80,000,000

IPO

Dec 2017

110,404,457

Reported

Jul 2022 (pre-Jieya)

about 136.8 m

Derived from Wang Yueren's 30,207,162 shares = 22.08%

Jul 2022 (post-Jieya)

about 174.7 m

Derived: +37,888,166

Aug 2025 (post 10:1)

30,054,138

Reported

Mar 2026 (post CEO placement)

37,348,303

Reported

Mid-2026 (post 5:1)

about 7,469,660

Reported as planned

Jul 2026 (post June placement)

about 16.7 m

Derived: 700,000 shares = 4.2%; CEO 4,655,309 shares = 27.93%

31 Aug 2026 (post 27 Aug consolidation and KRW 48 bn placement)

about 11.2–11.3 m

Derived: CEO 4,131,061 = 36.89%; market cap ÷ price

Valuation Multiples

MultipleCXIBasis

P/E (TTM)

about 6.0x

KRW 52.1 bn ÷ TTM Mar-2026 NI of KRW 8.65 bn [S25][S29]

P/B

about 0.1x

KRW 52.1 bn ÷ June 2025 equity of KRW 491.6 bn, before the 2026 capital raises [S2]

EV/Sales (TTM)

about 0.1x

(KRW 52.1 bn − KRW 47.1 bn March-2026 cash) ÷ KRW 51.4 bn. Excludes the August KRW 48 bn raise and the pending AIDT outflow

EV/EBITDA

Not computable

Operating income is negative TTM; quarterly D&A detail is partial

Capital Markets — Analyst consensus

ItemStatus

Analyst consensus

No active coverage identified ("reports 0")

Historical coverage

Hana Daetoo Buy, TP KRW 6,400 (May 2014)

Dividend history

No dividends paid

Dividend policy

Management cites the capital reduction as groundwork for future returns; no policy adopted

Buyback authorisation

None. CEO personal purchase plan only

Credit ratings (Moody's, S&P, Fitch)

Not rated

Debt maturity profile

No disclosed borrowings (total liabilities KRW 2.5 bn, June 2025)

Analyst Conclusions

Management guidance

No quantitative guidance has been disclosed. The qualitative priorities are profitability, core-business competitiveness, new growth engines and financial efficiency [S6], plus the AIDT consolidation [S3]. The only forward numbers are a third-party projection for AIDT (2027 revenue of about USD 52.07 m; about 40% CAGR to 2029) [S3]. That projection is inconsistent with AIDT's H1 2026 run-rate.

Consensus

None available [S29].

Bull case (grounded in data)

  1. Earnings reset from AIDT. AIDT's H1 2026 operating profit of USD 7.24 m (about KRW 10.5 bn) at a 19.6% margin [S3] compares with CXI's TTM net income of KRW 8.65 bn [S25]. Even after the 45% minority share, attributable AI profit could exceed the legacy business's recent earnings.

  2. Deep discount to book. A market cap of about KRW 52 bn against KRW 491.6 bn of June 2025 equity [S2][S29] leaves large upside if asset quality is confirmed and cash can be distributed.

  3. Aligned controller. The CEO holds 36.89%, has bought shares at premiums (67.7% in March), and has locked them up for 3 years voluntarily [S4][S12].

Bear case (grounded in data)

  1. Core business in freefall. Quarterly revenue is down about 61% from June 2025 to March 2026, with gross losses [S27]. A heavy D&A load (about 50% of revenue) means losses persist without a volume recovery [S25].

  2. Balance-sheet opacity. About KRW 153 bn of cash left the balance sheet in nine months while non-current assets rose about KRW 245 bn [S26], with no reconciliation available. Book value may not be realisable for minority holders, especially given PRC fund-transfer constraints [S13].

  3. Serial dilution and listing risk. Two consolidations in 12 months, a par reduction, and placements totalling at least about KRW 60 bn in 2026 [S2][S4][S5][S12]. KOSDAQ thresholds remain binding if the price falls back.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableWhy it matters
Publication and audit opinion of the FY2026 annual reportConfirms FY2026 losses, reconciles the cash movement, reveals the auditor's opinion
AIDT closing, accounting treatment and first consolidated quarterTests the revenue and margin claims
Use of the KRW 48 bn placement proceedsWhether it funds AIDT or other uses
CEO purchase execution (8 Oct – 6 Nov 2026)Signal of alignment
Market cap staying above KRW 20 bn and price above KRW 1,000KOSDAQ listing maintenance
Q1 FY2027 (Jul–Sep 2026) legacy revenueWhether the health-food decline has bottomed
Any dividend or return policyManagement has linked the capital reduction to future returns
Disclosure of AIDT's customers, data-compliance status and managementAssesses quality of earnings

Analyst verdict

CXI Healthcare Technology Group is no longer an investment in Chinese health supplements. It is now a special situation, and three facts define it.

First, the legacy business is deteriorating fast. Revenue in the March 2026 quarter was KRW 7.5 bn, against KRW 19.3 bn nine months earlier. The cost base is dominated by depreciation of plantation-type assets, so the business is posting gross losses [S25][S27]. There is no disclosed plan to reverse this beyond a small cosmetics-distribution push [S7].

Second, the balance sheet is both the bull case and the main concern. Reported equity of nearly KRW 500 bn with almost no liabilities [S2] sits next to a market cap of about KRW 52 bn [S29]. That gap has persisted for years, which suggests investors doubt the assets can be realised for minority holders. The KRW 153 bn fall in cash in the nine months to March 2026, matched by a rise in non-current assets [S26], sharpens that doubt until audited statements explain it.

Third, control and direction are now clearly with CEO Lin Jinsheng. He has put in roughly KRW 30 bn in 2026 at premium prices [S4][S5]. He is redirecting the company into enterprise AI through the 55% AIDT purchase, a business that on its own H1 2026 figures is larger and faster-growing than CXI [S3].

The investment case therefore rests on two verifiable questions:

  1. Do the FY2026 audited accounts clarify where the cash went, with a clean audit opinion?

  2. Do AIDT's revenue and profit translate into consolidated, cash-backed results, given the internal inconsistency between its run-rate and the valuer's 2027 projection?

Until both are answered, the stock should be treated as a high-risk, event-driven position, not a value investment. On the evidence currently available, governance and disclosure risk outweighs the apparent discount to book.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior roles / background

Lin Jinsheng (林金生 / 린진성; also listed as Jin Sheng Lin or Jin Lin)

CEO (대표이사); largest shareholder since Mar 2026

CEO since at least Oct 2012

Led the company through the China King Highway and CKH eras

Wang Yueren (王岳仁 per romanization)

Chairman (2010); "President" (2022); largest shareholder at 22.08% before Jul 2022

—

Founder-era chairman; Canadian national

Board & Management Changes

DateChangeContext

Feb 2026

CEO announces intention to raise stake (to 16.96% post-subscription, as planned then)

Listing-maintenance programme

13 Mar 2026

CEO becomes largest shareholder with 4,776,547 shares (12.8%)

Premium third-party placement at KRW 730 with a 3-year lock-up

21 Jul 2026

CEO stake to rise from 27.93% to 36.45% through a KRW 19.2 bn subscription

KRW 48 bn placement

31 Aug 2026

CEO reports 4,131,061 shares (36.89%)

After consolidation (27 Aug) and placement (31 Aug)

Major Shareholders

HolderStakeDateStatus

Lin Jinsheng (CEO)

36.89% (4,131,061 shares)

31 Aug 2026

Latest

Chen Aizhu (천아이주)

7.03% (2,112,519 shares after 10:1 consolidation)

11 Aug 2025

—

Ruixing International Holdings Ltd (Hong Kong)

16.24%

Jul 2022

—

Wang Yueren

22.08% (30,207,162 shares, before the Jieya issue)

Jul 2022

—

Other subscribers to the Jul 2026 KRW 48 bn placement (KRW 28.8 bn not taken by the CEO)

—

Aug 2026

—

“—” = not publicly disclosed.

Competitive Landscape

Competitors by Segment

SegmentCompetitorListingRelevanceLatest revenue (verified)

Health supplements (VDS)

By-health (汤臣倍健)

SZSE 300146

China VDS leader with 9.3% share (2024)

RMB 6,265.5 m (FY2025)

TCM fungal/cordyceps-derived products

Zhejiang Zuoli Pharmaceutical (佐力药业)

SZSE 300181

Medicinal-fungus leader (Wuling and Bailing series); owns a Qinghai cordyceps unit

RMB 3,041 m (FY2025)

TCM health products

Beijing Tong Ren Tang

SSE

Heritage TCM brand

—

Health supplements (direct selling)

Infinitus (Lee Kum Kee Health)

Private

Major TCM-health direct seller

—

Health supplements (direct selling)

Amway China; Perfect (China)

Private / subsidiaries

Large supplement direct sellers

—

Cordyceps-fermentation pharma

Jiangxi Jemincare (Jinshuibao capsule)

Private

Cordyceps-derived OTC

—

Tea

Large Pu'er and tea brand owners (e.g., Menghai Tea / Dayi)

Private

Pu'er competition

—

Cosmetics distribution

Brand-partner e-commerce operators (e.g., Baozun)

NASDAQ/HKEX

Foreign-brand distribution in China

—

AI training data (post-AIDT)

Beijing Haitian Ruisheng (海天瑞声)

SSE STAR 688787

A-share AI training-data specialist

RMB 377.0 m (FY2025)

AI training data (post-AIDT)

Appen; Datatang; Innodata

ASX; private; NASDAQ

Global and Chinese data-service peers

—

Peer Comparison FY2024

MetricCXI (FY Jun-2025)By-health (FY Dec-2025)Zuoli Pharma (FY Dec-2025)Haitian Ruisheng (FY Dec-2025)

Revenue

KRW 57.6 bn

RMB 6,265.5 m

RMB 3,041 m

RMB 377.0 m

Revenue growth YoY

-18.2%-8.4%+18.0%+59.0%

Net income

KRW 12.7 bn

RMB 782.2 m

RMB 632 m

RMB 14.1 m

Net margin

22.1%12.5%20.8%3.7%

Gross margin

~30.0% (derived)

67.4% (FY2024 main business)

63.0% (H1 2025)

48%

Recent Developments

Only 23 dated entries could be verified for the 18-month window.

Company Snapshot

$40.5M

Revenue

378

Employees

2009

Founded

SWOT Analysis

Strengths

  • Almost no leverage. Total liabilities were KRW 2.5 bn against equity of KRW 491.6 bn at June 2025 [S2].
  • Large reported asset base of KRW 575.2 bn at March 2026 against a KRW 52.1 bn market cap [S26][S29].
  • Committed controller. The CEO has invested about KRW 10.7 bn (March and June 2026) plus KRW 19.2 bn in August, at premium prices with a 3-year voluntary lock-up on the March shares [S4][S5].
  • Vertical integration. The group owns herbal (2015) and Pu'er tea (2020) plantations and a tea R&D lab [S16][S10][S8].
  • Profitable through FY2025. Net income was KRW 29.7 bn in FY2024 and KRW 12.7 bn in FY2025 [S11][S2].
  • Long listing history on KOSDAQ since March 2010, with a record of executing complex capital actions (two consolidations, a par reduction, several placements) [S18][S2][S12].

Weaknesses

  • Collapsing revenue. Quarterly revenue fell from KRW 19.30 bn (June 2025) to KRW 7.52 bn (March 2026) [S27].
  • Gross losses. COGS exceeded revenue in the December 2025 and March 2026 quarters [S27].
  • High fixed asset charges. Depreciation and amortisation in COGS was KRW 25.8 bn TTM, about 50% of revenue [S25].
  • Unexplained cash movement. Cash fell from KRW 200.5 bn to KRW 47.1 bn in nine months while non-current assets rose by about KRW 245 bn [S26].
  • Low gross margin vs peers: about 30% against 63–67% at Zuoli and By-health [S25][S32][S33].

Opportunities

  • AIDT consolidation. H1 2026 revenue of USD 36.97 m and operating profit of USD 7.24 m could roughly double group revenue and restore profit [S3].
  • AI data demand. Peer Haitian Ruisheng grew 59% in 2025 and its new orders more than doubled in Q1 2026 [S34].
  • K-indie brand portfolio. The task force is working with several more brands for China [S7].
  • Shareholder returns. Management says the capital reduction lays groundwork for dividends [S2]. Large book equity could support returns if cash can be repatriated.
  • Re-rating from deep discount. The market cap is about a tenth of reported equity (derived), so evidence of asset quality could re-rate the stock.
  • Tea-extract cosmetic ingredients through the Beautyskin R&D tie-up [S8].

Threats

  • KOSDAQ delisting regime. A KRW 20 bn market-cap floor and sub-KRW 1,000 rules have applied since 1 July 2026 [S2]. The market cap was KRW 12.6–14.6 bn at times in mid-2026 (Valueline snapshots) [S25][S26].
  • Dilution and overhang. The KRW 48 bn placement at KRW 6,000 added about 8 m shares (derived), and Korean press notes such placements can create overhang [S5].
  • Execution and integration risk in AI. The AIDT revenue figures are internally inconsistent, and the company has no AI track record [S3].
  • Chinese supplement slowdown. The category leader's revenue fell 27.3% in 2024 and 8.4% in 2025 [S31][S32].
  • "China discount" and governance perception. Korea-listed Chinese companies have suffered sector-wide re-ratings and auditor issues historically [S38].
  • Regulatory approval risk. The 2016 product pipeline depended on CFDA administrative approval, with past delays of two years [S23].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
7 Apr 2025Share price all-time low of KRW 49 (pre-consolidation) [S28]Exposure to sub-KRW 1,000 delisting reforms
Jun 2025 (quarter)Q4 FY2025 revenue KRW 19.30 bn; operating income KRW 7.57 bn [S27]Last strong quarter before the decline
11 Jul 2025Reporting-obligation date for the 10:1 share consolidation [S11]Shares in issue cut tenfold to 30,054,138
11 Aug 2025Chen Aizhu reports an unchanged 7.03% after consolidation [S11]Confirms a major non-management holder
FY2025 (Jul 2024 – Jun 2025)Revenue KRW 57.6 bn; net income KRW 12.7 bn; assets KRW 494.2 bn; equity KRW 491.6 bn; liabilities KRW 2.5 bn [S2]Profitable but shrinking (−18.2% revenue, derived)
Sep 2025 (quarter)Q1 FY2026 revenue KRW 16.75 bn; derived operating income KRW 4.95 bn [S27]Margin compression begins
16 Oct 2025Answer Garden exclusive China distribution; K-indie task force formed [S7]Cosmetics strategy refresh
Dec 2025 (quarter)Q2 FY2026 revenue KRW 7.87 bn; gross loss; net loss KRW 2.45 bn [S27][S28]Revenue more than halves quarter on quarter
Feb 2026Listing-maintenance and value-up programme announced [S6]Response to tighter KOSDAQ rules
Feb–Mar 2026Wave of share consolidations across KOSDAQ biotech/health names ahead of coin-stock rules [S35]Sector context
13 Mar 2026CEO placement completed at KRW 730 (67.7% premium), 3-year lock-up; CEO becomes largest holder at 12.8% [S4]Change of largest shareholder
Mar 2026 (quarter)Q3 FY2026 revenue KRW 7.52 bn; gross loss; net loss KRW 1.50 bn; cash KRW 47.1 bn [S26][S27][S28]Continued losses; sharp cash decline
24 Mar 202680% capital reduction (par USD 0.5 to 0.1) and 5:1 consolidation planned, to finish by end-June [S2]Pre-emptive compliance
Jun 2026Second CEO-backed placement (Mar + Jun CEO total about KRW 10.7 bn); trading halted around consolidation [S5][S25]Further recapitalisation
26 Jun 2026Shares trade at KRW 1,053 after resumption, −28.17% from a KRW 1,466 base [S2][S29]Post-consolidation price discovery
1 Jul 2026New KOSDAQ delisting standards take effect (KRW 20 bn market-cap floor; sub-KRW 1,000 rule) [S2]Regulatory pressure point
21 Jul 2026KRW 48 bn third-party placement announced; CEO KRW 19.2 bn for 3.2 m shares; payment due 28 Aug [S5]Major capital raise
21 Jul 2026CEO plans 700,000-share on-market purchase, 8 Oct – 6 Nov 2026 [S5]Insider-buying signal
27 Aug 2026Share consolidation effective (per CEO filing notes) [S12]Second consolidation of 2026
31 Aug 2026Placement shares effective; CEO reports 36.89% [S12]Control consolidated
~Sep 2026Full-year FY2026 results pending verification
8 Oct 2026CEO purchase window opens [S5]Ongoing
13 Oct 2026Decision to acquire 55% of AIDT Technologies for USD 45.37 m [S3]Strategic pivot to AI
14 Oct 2026Stock hits the daily +30% limit at KRW 4,595; market cap about KRW 52.1 bn [S29]Market reaction to AI pivot

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment: Total revenue fell from KRW 70,400 Mn in FY2024 to KRW 57,600 Mn in FY2025.
CXI Healthcare Technology Group Limited — Revenue by Segment
Series (KRW Mn)FY2024FY2025
Total revenue70,40057,600

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. S1Simply Wall St — CXI Healthcare Technology Group (company profile; TTM to 31 Dec 2025) (simplywall.st)
  2. S2Asia Economy (아시아경제), 24 Mar 2026 — capital reduction and share consolidation; FY2025 figures (core.asiae.co.kr)
  3. S3Asia Economy, 14 Oct 2026 — AIDT Technologies 55% acquisition (core.asiae.co.kr)
  4. S4Asia Economy, 13 Mar 2026 — CEO placement completed (KRW 730; 3-year lock-up) (core.asiae.co.kr)
  5. S5Asia Economy, 22 Jul 2026 — KRW 48 bn placement; CEO purchase plan (core.asiae.co.kr)
  6. S6Asia Economy, 23 Feb 2026 — listing-maintenance and value-up programme (core.asiae.co.kr)
  7. S7Asia Economy, 16 Oct 2025 — Answer Garden China distribution (core.asiae.co.kr)
  8. S8Asia Economy, 8 Oct 2024 — Beautyskin placement and MOU (core.asiae.co.kr)
  9. S9Asia Economy, 27 Mar 2019 — Humedix MOU; Korean subsidiary established (view.asiae.co.kr)
  10. S10Asia Economy, 30 Nov 2020 — Q1 FY2021 return to profit; divisions (core.asiae.co.kr)
  11. S11Digital Today AI disclosure — Chen Aizhu ownership report (Aug 2025); financial summary (digitaltoday.co.kr)
  12. S12TokenPost — Lin Jinsheng ownership report (31 Aug 2026) (tokenpost.kr)
  13. S13Dealsite, 14 Jul 2022 — Jieya Star deal; history; shareholder (dealsite.co.kr)
  14. S14Dealsite, 20 Jul 2022 — Jieya Star investment completed (dealsite.co.kr)
  15. S15Dealsite, 26 Aug 2022 — TUNEMAKERS distribution agreement (dealsite.co.kr)
  16. S16Dealsite / Paxnet, 21 Oct 2016 — CEO interview (12 new products) (dealsite.co.kr)
  17. S17Financial News, 23 Oct 2020 — Watsons China agreement (fnnews.com)
  18. S18Company IR deck, Jul 2019 (via Alphasquare) — , 회사소개 및 신규사업에 대한 설명(중국).pdf (file.alphasquare.co.kr)
  19. S19Toyo Economy, 29 Mar 2010 — IPO subscription results (sateconomy.co.kr)
  20. S20Jaekyung Ilbo, Mar 2010 — IPO overview (news.jkn.co.kr)
  21. S21Money Today, 6 Dec 2010 — China King interview (mt.co.kr)
  22. S22eToday, 30 Oct 2012 — Lin Jinsheng interview (etoday.co.kr)
  23. S23Hankyung, 9 Apr 2015 — Chinese-national stocks; CKH results (hankyung.com)
  24. S24NewsTomato, 27 May 2014 — Hana Daetoo Buy rating (newstomato.com)
  25. S25Valueline Korea — income statement, 900120 (annualised series) (valueline.co.kr)
  26. S26Valueline Korea — balance sheet, 900120 (valueline.co.kr)
  27. S27Google Finance — 900120:KOSDAQ (quarterly income statement) (google.com)
  28. S28TradingView — KRX:900120 (tradingview.com)
  29. S29StockHub — 900120 (Korean and English pages) (stockhub.kr)
  30. S30Morningstar Australia — 900120 company profile (morningstar.com.au)
  31. S31China Securities Journal — By-health FY2025 annual report summary (epaper.cs.com.cn)
  32. S31bROIC.ai — By-health quote page (roic.ai)
  33. S32Quartr — By-health Q4 2024 summary (9.3% VDS share; channel trends) (quartr.com)
  34. S33Securities Market Weekly — Zuoli FY2025; Zuoli FY2024 annual summary (cninfo) (static.weeklyonstock.com)
  35. S34Stockstar / Eastmoney — Haitian Ruisheng FY2025 results (stock.stockstar.com)
  36. S35Dailypharm, 12 Mar 2026 — coin-stock consolidation wave (dailypharm.com)
  37. S36Asia Economy, 13 Oct 2020 and 29 Jun 2020 — theme-driven price moves (cm.asiae.co.kr)
  38. S37MyDailyByte — 900120 company overview (brands, channels) (mydailybyte.com)
  39. S38NewsTomato, 16 Jun 2014 — Korea-listed Chinese companies discount (newstomato.com)

End of dossier.

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.